Erlotinib monotherapy for advanced non-small-cell lung cancer at a medical center in northern taiwan
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Poster
- By: CHEN, Ying-Ying (Cathy General Hospital, Taipei, China Taiwan)
- Co-author(s): Kao, Chi-Lan (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
Huang, Wan-Tsui (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
Lin, Hsi-Yen (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
INTRODUTION: Erlotinib is one of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) that are the standard therapies in advanced non-small-cell lung cancer (NSCLC) and is tolerable for some patients unfit for chemotherapy. AIMS: To evaluate the efficacy and tolerability of erlotinib monotherapy. METHODS: From March.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.